Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac resynchronisation therapy in heart failure: current status.

J Claude Daubert1, Christophe Leclercq, Erwan Donal

  • 1Département de Cardiologie et Maladies vasculaires, CHU Rennes, France.

Heart Failure Reviews
|August 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early complications and long-term outcome of patients treated with a Subcutaneous Cardioverter-Defibrillator: temporal trends and clinical implications of the anesthetic strategies adopted at implant.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

One-Year Outcomes of the First 1000 Patients Implanted With the Medtronic Micra AV Leadless Pacing System in France: The AV-CESAR Cohort Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Safety and performance of a novel ICD lead for left bundle branch area pacing: Results from the ASCEND CSP trial.

Heart rhythm·2026
Same author

The HONEST Cohort Study: Rationale and Design of a Nationwide Subcutaneous Implantable Cardioverter-Defibrillator Cohort.

JACC. Advances·2026
Same author

Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.

JACC. Clinical electrophysiology·2026
Same author

Catheter Ablation of atrial fibrillation vs. atrioventricular nodal ablation with Conduction system pacing in persistent atrial fibrillation and heart failure (ABACUS): rationale and design.

European heart journal open·2026

Cardiac resynchronization therapy improves heart failure outcomes for eligible patients. This therapy reduces mortality and hospitalizations, but further research is needed for specific patient groups.

Area of Science:

  • Cardiology
  • Medical Devices

Background:

  • Cardiac resynchronization therapy (CRT) has a 12-year history, with major advances from multi-center trials since 2001.
  • Previous trials included patients with LVEF ≤ 35% and QRS > 120 msec, showing benefits in reducing cardiovascular events and improving ventricular function.

Purpose of the Study:

  • To review the established benefits and ongoing questions regarding CRT in heart failure management.
  • To identify patient subgroups and clinical scenarios where CRT's efficacy requires further investigation.

Main Methods:

  • Analysis of large multi-center trials on cardiac resynchronization therapy.
  • Review of patient inclusion criteria (LVEF, QRS duration) and follow-up periods (3-36 months).

Main Results:

Related Experiment Videos

  • CRT demonstrated positive effects in reducing composite endpoints of death or hospitalization for major cardiovascular events.
  • Improvements were observed in left ventricular dimensions and systolic function, even in NYHA class II patients.

Conclusions:

  • CRT is effective for NYHA class III-IV patients with LVEF < 35%, ventricular dilatation, and QRS ≥ 120 msec, improving symptoms and reducing morbidity/mortality.
  • Further research is needed to clarify optimal patient selection, including those with atrial fibrillation, narrow QRS, mild heart failure, or asymptomatic dysfunction, and to determine the optimal device configuration (biventricular vs. left ventricular, with or without defibrillator).